Pantothenate Kinase-Associated Neurodegeneration (PKAN)

Welcome to the PKAN Road Map

Looking for the PKAN My Med Team Social Network?

This page does not yet have a sponsor.

Interested in becoming one?  Email us at sponsor@mycitymed.com to learn more.

This page does not yet have a sponsor.

Interested in becoming one?  Email us at sponsor@mycitymed.com to learn more.

This page does not yet have a sponsor.

Interested in becoming one?  Email us at sponsor@mycitymed.com to learn more.

FDA Approves Radicava (edaravone) to Treat ALS

Regenerative Neurobiology

ALS Treatment Updates

 

Showing listings 1-9 of 4323

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

ALS Groups

 

This page does not yet have a sponsor.

Interested in becoming one?  Email us at sponsor@mycitymed.com to learn more.

Featured

View all

PKAN Updates

  • Buy vet and pet crematoria firm CVS 25 Jun 2017 16:17 Daily Mail We round up the Sunday newspaper share tips. This week, Midas looks at vet chain CVS Group and middle class clothing brand Joules, while the Sunday Telegraph analyses Royal Mail.  The Sunday Times meanwhile delves into why The Lady from the Provvy has …
  • Retrophin Announces Expansion of Intellectual Property Estate for Sparsentan with Newly Issued Patents in the United States and Europe 01 Jun 2017 12:23 GlobeNewswire SAN DIEGO, June 01, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO) have each issued a patent covering the Company’s product candidate …
  • The Investment Case For Retrophin 05 May 2017 16:57 Seeking Alpha Retrophin (NASDAQ:RTRX) is trading at an enterprise value of around $450 million while having three marketed products and what looks like a solid pipeline and a robust balance sheet that allows the company to pursue additional deals. I avoided Retrophin …
  • Retrophin's (RTRX) CEO Steve Aselage on Q1 2017 Results - Earnings Call Transcript 05 May 2017 00:32 Seeking Alpha Retrophin, Inc. (NASDAQ:RTRX) Q1 2017 Earnings Conference Call May 4, 2017 4:30 p.m. ET Executives Chris Cline - VP, IR Steve Aselage - CEO Neil McFarlane - COO Laura Clague - CFO Bill Rote - SVP, and Head of R&D Analysts Tim Lugo - William Blair Do …
  • Retrophin Reports First Quarter 2017 Financial Results 04 May 2017 20:09 GlobeNewswire Phase 3 FORT study of RE-024 in PKAN to begin dosing mid-2017 Protocol development underway for pivotal Phase 3 trial of sparsentan in FSGS First quarter revenues rose 16 percent to $34 million SAN DIEGO, May 04, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. ( …
  • Retrophin to Report First Quarter 2017 Financial Results 20 Apr 2017 20:38 GlobeNewswire April 20, 2017 16:30 ET | Source: Retrophin, Inc. SAN DIEGO, April 20, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced it will report first quarter 2017 financial results on Thursday, May 4, 2017 after the close of the U.S. …
  • Retrophin Appoints Ron Squarer to Board of Directors 12 Apr 2017 20:35 GlobeNewswire SAN DIEGO, April 12, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced the appointment of Ron Squarer to the Company’s Board of Directors, effective immediately. Mr. Squarer is chief executive officer and a director of Array BioPharma …
  • John A. Orwin Joins Retrophin Board of Directors 23 Mar 2017 21:32 GlobeNewswire SAN DIEGO, March 23, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced the appointment of John A. Orwin to the Company’s Board of Directors, effective immediately. Mr. Orwin currently serves as chief executive officer of Relypsa, Inc …
  • NephCure Kidney International® Launches the NephCure Accelerating Cures Institute® 21 Mar 2017 12:11 Kait Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please …
  • Small Cap Retrophin Has Room to Recover 03 Mar 2017 14:37 SmallCap Network On Thursday, our Under the Radar Movers newsletter suggested going long on small cap biopharmaceutical stock Retrophin Inc (NASDAQ: RTRX): “Two views of RTRX today. The short-term one shows how there's been a high-volume buy-in this week, and that …
  • Retrophin's (RTRX) CEO Steve Aselage on Q4 2016 Results - Earnings Call Transcript 02 Mar 2017 03:15 Seeking Alpha Retrophin, Inc. (NASDAQ:RTRX) Q4 2016 Results Conference Call March 01, 2017 05:00 PM ET Executives Chris Cline - Senior Director, IR Steve Aselage - CEO Neil McFarlane - COO Laura Clague - CFO Analysts Joseph Schwartz - Leerink Partners Liisa Bayko - JMP …
  • Retrophin Provides Sparsentan Regulatory Update; Reports Fourth Quarter and Full Year 2016 Financial Results 01 Mar 2017 21:10 GlobeNewswire Phase 3 trial of sparsentan in FSGS to initiate in second half of 2017; Interim analysis of proteinuria to serve as basis for NDA filing for accelerated approval Full year 2016 revenue grew 34% over 2015 to $134 million Conference call today at 5:00 p.m. …
  • Retrophin to Report Fourth Quarter and Full Year 2016 Financial Results 15 Feb 2017 21:47 GlobeNewswire February 15, 2017 16:30 ET | Source: Retrophin, Inc. SAN DIEGO, Feb. 15, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced it will report fourth quarter and full year 2016 financial results on Wednesday, March 1, 2017 after the close …
  • Retrophin Appoints William Rote Senior Vice President, Research and Development 13 Feb 2017 22:47 PharmiWeb.com Posted on: 13 Feb 17 SAN DIEGO, Feb. 13, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced William “Bill” Rote, Ph.D. has been appointed senior vice president, research and development, effective immediately. Dr. Rote will oversee all …
  • Appoints Elizabeth Reed General Counsel 05 Jan 2017 08:57 4-traders (GlobeNewswire) - Retrophin, Inc.(NASDAQ:RTRX) today announced Elizabeth Reed has been appointed general counsel and corporate secretary, effective immediately. Ms. Reed will be responsible for overseeing the Companys general legal, intellectual property, …
  • Retrophin Appoints Elizabeth Reed General Counsel 04 Jan 2017 21:54 GlobeNewswire SAN DIEGO, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced Elizabeth Reed has been appointed general counsel and corporate secretary, effective immediately. Ms. Reed will be responsible for overseeing the Company’s general …
  • Technical Reports on Drug Makers Equities -- Impax Labs, Retrophin, Heron Therapeutics, and GW Pharma 17 Nov 2016 12:27 4-traders NEW YORK, November 17, 2016 /PRNewswire/ -- Stock-Callers.com turns investors' focus on the Drug Manufacturers industry which has experienced moderate growth over the last five years due to rising demand for healthcare and medications …
  • Rare PKAN brain wasting condition overwhelms Queensland boy in TEN DAYS 16 Nov 2016 04:14 Daily Mail Little Miller Cashen still smiles despite knowing he will never walk or talk again.  The six-year-old's brain is wasting away as he battles a rare degenerative illness which is likely to claim his life one day. In just over a year the bright and …
  • She can't cure him, but she can make him smile 01 Nov 2016 08:37 Sunshine Coast Daily AROONA'S Sophie Cashen cannot make her six-year-old son, Miller, walk or talk again but she can make the world a better place for him every day he has left in it. Life changed forever for Sophie and Miller in August last year when he caught a cold, …
  • Ceviche Fund Update: Improved Performance And 3 New Buys 26 Oct 2016 19:04 Seeking Alpha For new readers, please read my initial post on the launch of the Ceviche Model Fund and rules/guidelines involved. Performance To start off on a bright note, performance for the Ceviche Fund has improved slightly, as slight gains in Corcept (NASDAQ: …

This page does not yet have a sponsor.

Interested in becoming one?  Email us at sponsor@mycitymed.com to learn more.

[google_news query=’als’ topic=snc topic=t topic=b topic=s topic=m]

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

©2017 My City Med. All Rights Reserved.

or

Log in with your credentials

or    

Forgot your details?

or

Create Account

Skip to toolbar